Skip to main content Accessibility help
×
Hostname: page-component-74d7c59bfc-2tr8t Total loading time: 0 Render date: 2026-02-06T15:52:31.214Z Has data issue: false hasContentIssue false

Chapter 22 - Medication-induced stroke

from Section VII - Other uncommon causes of iatrogenic stroke

Published online by Cambridge University Press:  20 October 2016

By
Fazeel M. Siddiqui  and
Adnan I. Qureshi
Edited by
Alexander Tsiskaridze ,
Arne Lindgren  and
Adnan I. Qureshi
Alexander Tsiskaridze
Affiliation:
Sarajishvili Institute of Neurology, Tblisi State University, Georgia
Arne Lindgren
Affiliation:
Department of Neurology, University Hospital Lund, Sweden
Adnan I. Qureshi
Affiliation:
Department of Neurology, University of Minnesota
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Chapter
Information
Treatment-Related Stroke
Including Iatrogenic and In-Hospital Strokes
 , pp. 227 - 240
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Tisdale, J E, Miller, D A. American Society of Health-System Pharmacists. Drug-induced Diseases: Prevention, Detection, and Management. Bethesda, MD: American Society of Health-System Pharmacists; 2005.Google Scholar
Flaherty, M L. Anticoagulant-associated intracerebral hemorrhage. Seminars in Neurology. 2010; 30:565–72.CrossRefGoogle ScholarPubMed
Cantu, C, Arauz, A, Murillo-Bonilla, L M, Lopez, M, Barinagarrementeria, F. Stroke associated with sympathomimetics contained in over-the-counter cough and cold drugs. Stroke. 2003; 34:1667–72.CrossRefGoogle ScholarPubMed
Jain, K K. Drug-induced Neurological Disorders. Cambridge, MA: Hogrefe Pub; 2012.Google Scholar
Plu-Bureau, G, Hugon-Rodin, J, Maitrot-Mantelet, L, Canonico, M. Hormonal contraceptives and arterial disease: An epidemiological update. Best Practice & Research. Clinical Endocrinology & Metabolism. 2013; 27:35–45.CrossRefGoogle ScholarPubMed
Plu-Bureau, G, Maitrot-Mantelet, L, Hugon-Rodin, J, Canonico, M. Hormonal contraceptives and venous thromboembolism: An epidemiological update. Best Practice & Research. Clinical Endocrinology & Metabolism. 2013; 27:25–34.CrossRefGoogle ScholarPubMed
Godsland, I F, Winkler, U, Lidegaard, O, Crook, D. Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms. Drugs. 2000; 60:721–869.CrossRefGoogle ScholarPubMed
Meade, T W, Greenberg, G, Thompson, S G. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-microgram oestrogen preparations. British Medical Journal. 1980; 280:1157–61.CrossRefGoogle Scholar
Lidegaard, O. Oral contraceptives, pregnancy and the risk of cerebral thromboembolism: The influence of diabetes, hypertension, migraine and previous thrombotic disease. British Journal of Obstetrics and Gynaecology. 1995; 102:153–9.Google ScholarPubMed
Lidegaard, O, Kreiner, S. Contraceptives and cerebral thrombosis: A five-year national case-control study. Contraception. 2002; 65:197–205.CrossRefGoogle ScholarPubMed
Chan, W S, Ray, J, Wai, E K, et al. Risk of stroke in women exposed to low-dose oral contraceptives: A critical evaluation of the evidence. Archives of Internal Medicine. 2004; 164:741–7.CrossRefGoogle ScholarPubMed
Schurks, M, Rist, P M, Bigal, M E, et al. Migraine and cardiovascular disease: Systematic review and meta-analysis. British Medical Journal. 2009; 339:b3914.CrossRefGoogle ScholarPubMed
Saposnik, G, Barinagarrementeria, F, Brown, R D Jr., et al. Diagnosis and management of cerebral venous thrombosis: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42:1158–92.CrossRefGoogle ScholarPubMed
Saadatnia, M, Naghavi, N, Fatehi, F, Zare, M, Tajmirriahi, M. Oral contraceptive misuse as a risk factor for cerebral venous and sinus thrombosis. Journal of Research in Medical Sciences. 2012; 17:344–7.Google ScholarPubMed
Ashjazadeh, N, Borhani Haghighi, A, Poursadeghfard, M, Azin, H. Cerebral venous-sinus thrombosis: A case series analysis. Iranian Journal of Medical Sciences. 2011; 36:178–82.Google ScholarPubMed
Martinelli, I, Sacchi, E, Landi, G, et al. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. New England Journal of Medicine. 1998; 338:1793–7.CrossRefGoogle ScholarPubMed
de Bruijn, S F, Stam, J, Koopman, M M, Vandenbroucke, J P. The Cerebral Venous Sinus Thrombosis Study Group. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. British Medical Journal. 1998; 316:589–92.CrossRefGoogle ScholarPubMed
Dentali, F, Crowther, M, Ageno, W. Thrombophilic abnormalities, oral contraceptives, and risk of cerebral vein thrombosis: A meta-analysis. Blood. 2006; 107:2766–73.CrossRefGoogle ScholarPubMed
Dunne, C, Malyuk, D, Firoz, T. Cerebral venous sinus thrombosis in a woman using the etonogestrel-ethinyl estradiol vaginal contraceptive ring: A case report. Journal of Obstetrics and Gynaecology Canada. 2010; 32:270–3.CrossRefGoogle Scholar
Shetty, K D, Vogt, W B, Bhattacharya, J. Hormone replacement therapy and cardiovascular health in the United States. Medical Care. 2009; 47:600–6.CrossRefGoogle ScholarPubMed
Rossouw, J E, Anderson, G L, Prentice, R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the women’s health initiative randomized controlled trial. Journal of the American Medical Association. 2002; 288:321–33.Google ScholarPubMed
Wassertheil-Smoller, S, Hendrix, S L, Limacher, M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: The women’s health initiative: A randomized trial. Journal of the American Medical Association. 2003; 289:2673–84.Google ScholarPubMed
Ruige, J B, Mahmoud, A M, De Bacquer, D, Kaufman, J M. Endogenous testosterone and cardiovascular disease in healthy men: A meta-analysis. Heart. 2011; 97:870–5.CrossRefGoogle ScholarPubMed
Yeap, B B, Hyde, Z, Almeida, O P, et al. Lower testosterone levels predict incident stroke and transient ischemic attack in older men. Journal of Clinical Endocrinology and Metabolism. 2009; 94:2353–9.CrossRefGoogle ScholarPubMed
Ferenchick, G, Schwartz, D, Ball, M, Schwartz, K. Androgenic-anabolic steroid abuse and platelet aggregation: A pilot study in weight lifters. American Journal of the Medical Sciences. 1992; 303:78–82.CrossRefGoogle ScholarPubMed
Stergiopoulos, K, Brennan, J J, Mathews, R, Setaro, J F, Kort, S. Anabolic steroids, acute myocardial infarction and polycythemia: A case report and review of the literature. Vascular Health and Risk Management. 2008; 4:1475–80.CrossRefGoogle ScholarPubMed
Warkentin, T E, Greinacher, A, Koster, A, Lincoff, A M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133:340S–380S.CrossRefGoogle ScholarPubMed
Linkins, L A, Dans, A L, Moores, L K, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e495S–530S.CrossRefGoogle ScholarPubMed
Visentin, G P, Ford, S E, Scott, J P, Aster, R H. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. Journal of Clinical Investigation. 1994; 93:81–8.CrossRefGoogle ScholarPubMed
Newman, P M, Chong, B H. Heparin-induced thrombocytopenia: New evidence for the dynamic binding of purified anti-pf4-heparin antibodies to platelets and the resultant platelet activation. Blood. 2000; 96:182–7.CrossRefGoogle ScholarPubMed
Giossi, A, Del Zotto, E, Volonghi, I, et al. Thromboembolic complications of heparin-induced thrombocytopenia. Blood Coagulation & Fibrinolysis. 2012; 23:559–62.CrossRefGoogle ScholarPubMed
LaMonte, M P, Brown, P M, Hursting, M J. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Critical Care Medicine. 2004; 32:976–80.CrossRefGoogle ScholarPubMed
Li, S H, Chen, W H, Tang, Y, et al. Incidence of ischemic stroke post-chemotherapy: A retrospective review of 10,963 patients. Clinical Neurology and Neurosurgery. 2006; 108:150–6.CrossRefGoogle ScholarPubMed
Czaykowski, P M, Moore, M J, Tannock, I F. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. Journal of Urology. 1998; 160:2021–4.CrossRefGoogle ScholarPubMed
Wall, J G, Weiss, R B, Norton, L, et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: A cancer and leukemia group B study. American Journal of Medicine. 1989; 87:501–4.CrossRefGoogle ScholarPubMed
Bachaud, J M, David, J M, Shubinski, R E, et al. Predictive factors of a complete response to and adverse effects of a cddp-5fu combination as primary therapy for head and neck squamous carcinomas. Journal of Laryngology and Otology. 1993; 107:924–30.CrossRefGoogle ScholarPubMed
Skali, H, Parving, H H, Parfrey, P S, et al. Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with darbepoetin alfa: The trial to reduce cardiovascular events with aranesp therapy (treat) experience. Circulation. 2011; 124:2903–8.CrossRefGoogle ScholarPubMed
Pfeffer, M A, Burdmann, E A, Chen, C Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine. 2009; 361:2019–32.CrossRefGoogle ScholarPubMed
FDA Drug Safety Communication. Erythropoiesis-stimulating agents (ESAS): Procrit, epogen and aranesp. 2010.Google Scholar
FDA Drug Safety Communication. Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAS) in chronic kidney disease. 2011.Google Scholar
Ehrenreich, H, Weissenborn, K, Prange, H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40:e647–656.CrossRefGoogle ScholarPubMed
Fergusson, D A, Hebert, P C, Mazer, C D, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine. 2008; 358:2319–31.CrossRefGoogle ScholarPubMed
Mangano, D T, Tudor, I C, Dietzel, C. The risk associated with aprotinin in cardiac surgery. New England Journal of Medicine. 2006; 354:353–65.CrossRefGoogle ScholarPubMed
Roberts, I, Perel, P, Prieto-Merino, D, et al. Effect of tranexamic acid on mortality in patients with traumatic bleeding: Prespecified analysis of data from randomised controlled trial. British Medical Journal. 2012; 345:e5839.CrossRefGoogle ScholarPubMed
Roos, Y B, Rinkel, G J, Vermeulen, M, Algra, A, van Gijn, J. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database of Systematic Reviews. 2003: CD001245.CrossRefGoogle Scholar
Idbaih, A, Crassard, I, Vahedi, K, Guichard, J P, Woimant, F. Thrombotic cocktail in stroke. Neurology. 2005; 64:334.CrossRefGoogle ScholarPubMed
Brown, J E, Olujohungbe, A, Chang, J, et al. All-trans retinoic acid (ATRA) and tranexamic acid: A potentially fatal combination in acute promyelocytic leukaemia. British Journal of Haematology. 2000; 110:1010–12.CrossRefGoogle ScholarPubMed
Caress, J B, Cartwright, M S, Donofrio, P D, Peacock, J E Jr. The clinical features of 16 cases of stroke associated with administration of IVIG. Neurology. 2003; 60:1822–4.CrossRefGoogle ScholarPubMed
Katz, U, Shoenfeld, Y. Review: Intravenous immunoglobulin therapy and thromboembolic complications. Lupus. 2005; 14:802–8.CrossRefGoogle ScholarPubMed
Orbach, H, Katz, U, Sherer, Y, Shoenfeld, Y. Intravenous immunoglobulin: Adverse effects and safe administration. Clinical Reviews in Allergy & Immunology. 2005; 29:173–84.CrossRefGoogle ScholarPubMed
Caress, J B, Hobson-Webb, L, Passmore, L V, Finkbiner, A P, Cartwright, M S. Case-control study of thromboembolic events associated with IV immunoglobulin. Journal of Neurology. 2009; 256:339–42.CrossRefGoogle ScholarPubMed
Haag, M D, Bos, M J, Hofman, A, et al. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Archives of Internal Medicine. 2008; 168:1219–24.CrossRefGoogle ScholarPubMed
Roumie, C L, Mitchel, E F Jr., Kaltenbach, L, et al. Nonaspirin NSAIDS, cyclooxygenase 2 inhibitors, and the risk for stroke. Stroke. 2008; 39:2037–45.CrossRefGoogle ScholarPubMed
Andersohn, F, Schade, R, Suissa, S, Garbe, E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: A nested case-control study. Stroke. 2006; 37:1725–30.CrossRefGoogle ScholarPubMed
Fosbol, E L, Olsen, A M, Olesen, J B, et al. Use of nonsteroidal anti-inflammatory drugs among healthy people and specific cerebrovascular safety. International Journal of Stroke. 2012; 9:943–5.Google ScholarPubMed
Chang, C H, Shau, W Y, Kuo, C W, Chen, S T, Lai, M S. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: A nationwide case-crossover study. Stroke. 2010; 41:1884–90.CrossRefGoogle ScholarPubMed
Bennett, J S, Daugherty, A, Herrington, D, et al. The use of nonsteroidal anti-inflammatory drugs (NSAIDS): A science advisory from the American Heart Association. Circulation. 2005; 111:1713–16.CrossRefGoogle ScholarPubMed
Antman, E M, Bennett, J S, Daugherty, A, et al. Use of nonsteroidal antiinflammatory drugs: An update for clinicians: A scientific statement from the American Heart Association. Circulation. 2007; 115:1634–42.CrossRefGoogle ScholarPubMed
Sklar, P, Masur, H. HIV infection and cardiovascular disease: Is there really a link? New England Journal of Medicine. 2003; 349:2065–7.CrossRefGoogle ScholarPubMed
Engstrom, J W, Lowenstein, D H, Bredesen, D E. Cerebral infarctions and transient neurologic deficits associated with acquired immunodeficiency syndrome. American Journal of Medicine. 1989; 86:528–32.CrossRefGoogle ScholarPubMed
Qureshi, A I, Janssen, R S, Karon, J M, et al. Human immunodeficiency virus infection and stroke in young patients. Archives of Neurology. 1997; 54:1150–3.CrossRefGoogle ScholarPubMed
Mochan, A, Modi, M, Modi, G. Protein S deficiency in HIV associated ischaemic stroke: An epiphenomenon of HIV infection. Journal of Neurology, Neurosurgery, and Psychiatry. 2005; 76:1455–6.CrossRefGoogle ScholarPubMed
Qureshi, A I. HIV infection and stroke: If not protein S deficiency then what explains the relationship? Journal of Neurology, Neurosurgery, and Psychiatry. 2005; 76:1331.CrossRefGoogle Scholar
Vaughn, G, Detels, R. Protease inhibitors and cardiovascular disease: Analysis of the Los Angeles County Adult Spectrum of Disease cohort. AIDS Care. 2007; 19:492–9.CrossRefGoogle ScholarPubMed
Monsuez, J J, Goujon, C, Wyplosz, B, et al. Cerebrovascular diseases in HIV-infected patients. Current HIV Research. 2009; 7:475–80.CrossRefGoogle ScholarPubMed
Corral, I, Quereda, C, Moreno, A, et al. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: Incidence and risk factors. Cerebrovascular Diseases. 2009; 27:559–63.CrossRefGoogle ScholarPubMed
Ortiz, G, Koch, S, Romano, J G, Forteza, A M, Rabinstein, A A. Mechanisms of ischemic stroke in HIV-infected patients. Neurology. 2007; 68:1257–61.CrossRefGoogle ScholarPubMed
Mangili, A, Gerrior, J, Tang, A M, et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: A study using carotid intima-media thickness and coronary artery calcium score. Clinical Infectious Diseases. 2006; 43:1482–9.CrossRefGoogle Scholar
Sen, S, Rabinstein, A A, Elkind, M S, Powers, W J. Recent developments regarding human immunodeficiency virus infection and stroke. Cerebrovascular Diseases. 2012; 33:209–18.CrossRefGoogle ScholarPubMed
Dobbs, M R, Berger, J R. Stroke in HIV infection and AIDS. Expert Review of Cardiovascular Therapy. 2009; 7:1263–71.CrossRefGoogle ScholarPubMed
Chen, S P, Fuh, J L, Wang, S J. Reversible cerebral vasoconstriction syndrome: Current and future perspectives. Expert Review of Neurotherapeutics. 2011; 11:1265–76.CrossRefGoogle ScholarPubMed
Salvarani, C, Brown, R D Jr., Hunder, G G. Adult primary central nervous system vasculitis. Lancet. 2012; 380:767–77.CrossRefGoogle ScholarPubMed
Calabrese, L H, Duna, G F. Drug-induced vasculitis. Current Opinion in Rheumatology. 1996; 8:34–40.CrossRefGoogle ScholarPubMed
Citron, B P, Halpern, M, McCarron, M, et al. Necrotizing angiitis associated with drug abuse. New England Journal of Medicine. 1970; 283:1003–11.CrossRefGoogle ScholarPubMed
Lim, D, Rademaker, M, Asztely, F, Ratnaweera, M, Coltman, G. Cerebral vasculitis and multi-focal neurological deficits due to allopurinol-induced hypersensitivity syndrome. Australasian Journal of Dermatology. 2013.CrossRefGoogle Scholar
Rothwell, P M, Grant, R. Cerebral vasculitis following allopurinol treatment. Postgraduate Medical Journal. 1996; 72:119–20.CrossRefGoogle ScholarPubMed
Flaherty, M L, Kissela, B, Woo, D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology. 2007; 68:116–21.CrossRefGoogle ScholarPubMed
Whitlock, R P, Sun, J C, Fremes, S E, Rubens, F D, Teoh, K H. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e576S–600S.CrossRefGoogle ScholarPubMed
You, J J, Singer, D E, Howard, P A, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e531S–575S.CrossRefGoogle ScholarPubMed
Ageno, W, Gallus, A S, Wittkowsky, A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141:e44S–88S.CrossRefGoogle ScholarPubMed
Hylek, E M, Skates, S J, Sheehan, M A, Singer, D E. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. New England Journal of Medicine. 1996; 335:540–6.CrossRefGoogle ScholarPubMed
Hart, R G, Boop, B S, Anderson, D C. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke. 1995; 26:1471–7.CrossRefGoogle Scholar
Fang, M C, Go, A S, Chang, Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. American Journal of Medicine. 2007; 120:700–5.CrossRefGoogle ScholarPubMed
Quinones-Hinojosa, A, Gulati, M, Singh, V, Lawton, M T. Spontaneous intracerebral hemorrhage due to coagulation disorders. Neurosurgical Focus. 2003; 15:E3.CrossRefGoogle ScholarPubMed
Hampton, K K, Preston, F E. ABC of clinical haematology. Bleeding disorders, thrombosis, and anticoagulation. British Medical Journal. 1997; 314:1026–9.CrossRefGoogle ScholarPubMed
Vernooij, M W, Haag, M D, van der Lugt, A, et al. Use of antithrombotic drugs and the presence of cerebral microbleeds: The Rotterdam scan study. Archives of Neurology. 2009; 66:714–20.CrossRefGoogle ScholarPubMed
Thompson, B B, Bejot, Y, Caso, V, et al. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: A systematic review. Neurology. 2010; 75:1333–42.CrossRefGoogle ScholarPubMed
Naidech, A M, Bendok, B R, Garg, R K, et al. Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery. 2009; 65:684–8.CrossRefGoogle ScholarPubMed
He, J, Whelton, P K, Vu, B, Klag, M J. Aspirin and risk of hemorrhagic stroke: A meta-analysis of randomized controlled trials. Journal of the American Medical Association. 1998; 280:1930–5.Google ScholarPubMed
Foerch, C, Sitzer, M, Steinmetz, H, Neumann-Haefelin, T. Pretreatment with antiplatelet agents is not independently associated with unfavorable outcome in intracerebral hemorrhage. Stroke. 2006; 37:2165–7.CrossRefGoogle Scholar
Toyoda, K, Okada, Y, Minematsu, K, et al. Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage. Neurology. 2005; 65:1000–4.CrossRefGoogle ScholarPubMed
Toyoda, K, Yasaka, M, Nagata, K, et al. Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The bleeding with antithrombotic therapy (BAT) retrospective study. Cerebrovascular Diseases. 2009; 27:151–9.CrossRefGoogle ScholarPubMed
Saloheimo, P, Ahonen, M, Juvela, S, et al. Regular aspirin-use preceding the onset of primary intracerebral hemorrhage is an independent predictor for death. Stroke. 2006; 37:129–33.CrossRefGoogle Scholar
Creutzfeldt, C J, Weinstein, J R, Longstreth, W T Jr., et al. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. Journal of Stroke & Cerebrovascular Diseases. 2009; 18:221–8.CrossRefGoogle ScholarPubMed
Caso, V, Paciaroni, M, Venti, M, et al. Effect of on-admission antiplatelet treatment on patients with cerebral hemorrhage. Cerebrovascular Diseases. 2007; 24:215–18.CrossRefGoogle ScholarPubMed
Roquer, J, Rodriguez Campello, A, Gomis, M, et al. Previous antiplatelet therapy is an independent predictor of 30-day mortality after spontaneous supratentorial intracerebral hemorrhage. Journal of Neurology. 2005; 252:412–16.CrossRefGoogle Scholar
Lacut, K, Le Gal, G, Seizeur, R, et al. Antiplatelet drug use preceding the onset of intracerebral hemorrhage is associated with increased mortality. Fundamental & Clinical Pharmacology. 2007; 21:327–33.CrossRefGoogle ScholarPubMed
Hanger, H C, Fletcher, V J, Wilkinson, T J, et al. Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. Journal of Neurology. 2008; 255:347–52.CrossRefGoogle ScholarPubMed
Sansing, L H, Messe, S R, Cucchiara, B L, et al. Prior antiplatelet use does not affect hemorrhage growth or outcome after ICH. Neurology. 2009; 72:1397–402.CrossRefGoogle ScholarPubMed
Moussouttas, M, Malhotra, R, Fernandez, L, et al. Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. Neurocritical Care. 2010; 12:24–9.CrossRefGoogle ScholarPubMed
Stead, L G, Jain, A, Bellolio, M F, et al. Effect of anticoagulant and antiplatelet therapy in patients with spontaneous intra-cerebral hemorrhage: Does medication use predict worse outcome? Clinical Neurology & Neurosurgery. 2010; 112:275–81.CrossRefGoogle ScholarPubMed
Ishibashi, A, Yokokura, Y, Adachi, H. Is antiplatelet therapy for the prevention of ischemic stroke associated with the prognosis of intracerebral hemorrhage? Kurume Medical Journal. 2008; 55:71–5.CrossRefGoogle ScholarPubMed
Nicolini, A, Ghirarduzzi, A, Iorio, A, et al. Intracranial bleeding: Epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. Haematologica. 2002; 87:948–56.Google ScholarPubMed
Baldi, G, Altomonte, F, Altomonte, M, et al. Intracranial haemorrhage in patients on antithrombotics: Clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. Cerebrovascular Diseases. 2006; 22:286–93.CrossRefGoogle Scholar
Lovelock, C E, Cordonnier, C, Naka, H, et al. Antithrombotic drug use, cerebral microbleeds, and intracerebral hemorrhage: A systematic review of published and unpublished studies. Stroke. 2010; 41:1222–8.CrossRefGoogle ScholarPubMed
Naidech, A M, Bernstein, R A, Levasseur, K, et al. Platelet activity and outcome after intracerebral hemorrhage. Annals of Neurology. 2009; 65:352–6.CrossRefGoogle ScholarPubMed
Naidech, A M, Jovanovic, B, Liebling, S, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke. 2009; 40:2398–401.CrossRefGoogle ScholarPubMed
de Gans, K, de Haan, R J, Majoie, C B, et al. PATCH: Platelet Transfusion in Cerebral Haemorrhage: Study protocol for a multicentre, randomised, controlled trial. BMC Neurology. 2010; 10:19.CrossRefGoogle ScholarPubMed
Memon, M A, Blankenship, J C, Wood, G C, Frey, C M, Menapace, F J. Incidence of intracranial hemorrhage complicating treatment with glycoprotein IIb/IIIa receptor inhibitors: A pooled analysis of major clinical trials. American Journal of Medicine. 2000; 109:213–17.CrossRefGoogle ScholarPubMed
Qureshi, A I, Suri, M F, Ali, Z, et al. Carotid angioplasty and stent placement: A prospective analysis of perioperative complications and impact of intravenously administered abciximab. Neurosurgery. 2002; 50:466–73.Google ScholarPubMed
Qureshi, A I, Saad, M, Zaidat, O O, et al. Intracerebral hemorrhages associated with neurointerventional procedures using a combination of antithrombotic agents including abciximab. Stroke. 2002; 33:1916–19.CrossRefGoogle ScholarPubMed
Adams, H P Jr., Effron, M B, Torner, J, et al. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial: Abciximab in emergency treatment of stroke trial (ABESTT-II). Stroke. 2008; 39:87–99.CrossRefGoogle ScholarPubMed
Adams, H P Jr., Leira, E C, Torner, J C, et al. Treating patients with “wake-up” stroke: The experience of the ABESTT-II trial. Stroke. 2008; 39:3277–82.CrossRefGoogle ScholarPubMed
Hirsh, J, Guyatt, G, Albers, G W, Harrington, R, Schunemann, H J, American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133:110S–112S.CrossRefGoogle ScholarPubMed
The National Institute of Neurological Disorders and Stroke RT-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine. 1995; 333:1581–7.Google Scholar
Strbian, D, Sairanen, T, Meretoja, A, et al. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011; 77:341–8.CrossRefGoogle ScholarPubMed
Herrmann, N, Lanctot, K L. Do atypical antipsychotics cause stroke? CNS Drugs. 2005; 19:91–103.CrossRefGoogle ScholarPubMed
Sacchetti, E, Turrina, C, Valsecchi, P. Cerebrovascular accidents in elderly people treated with antipsychotic drugs: A systematic review. Drug Safety. 2010; 33:273–88.CrossRefGoogle ScholarPubMed
Christensen, S, Mehnert, F, Chapurlat, R D, Baron, J A, Sorensen, H T. Oral bisphosphonates and risk of ischemic stroke: A case-control study. Osteoporosis International. 2011; 22:1773–9.CrossRefGoogle ScholarPubMed
Wilkinson, G S, Baillargeon, J, Kuo, Y F, Freeman, J L, Goodwin, J S. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. Journal of Clinical Oncology. 2010; 28:4898–905.CrossRefGoogle ScholarPubMed
Gallagher, A M, Smeeth, L, Seabroke, S, Leufkens, H G, van Staa, T P. Risk of death and cardiovascular outcomes with thiazolidinediones: A study with the general practice research database and secondary care data. PloS One. 2011; 6:e28157.CrossRefGoogle ScholarPubMed
Panicker, G K, Karnad, D R, Salvi, V, Kothari, S. Cardiovascular risk of oral antidiabetic drugs: Current evidence and regulatory requirements for new drugs. J Assoc Physicians India. 2012; 60:56–61.Google ScholarPubMed
Morgenstern, L B, Hemphill, J C 3rd, Anderson, C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010; 41:2108–29.CrossRefGoogle ScholarPubMed
Jauch, E C, Saver, J L, Adams, H P Jr. et al. Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44:870–947.CrossRefGoogle ScholarPubMed
Ducros, A, Bousser, M G. Reversible cerebral vasoconstriction syndrome. Practical Neurology. 2009; 9:256–67.CrossRefGoogle ScholarPubMed
Mittal, M K, Rabinstein, A A. Anticoagulation-related intracranial hemorrhages. Current Atherosclerosis Reports. 2012; 14:351–9.CrossRefGoogle ScholarPubMed
Hirsh, J, Anand, S S, Halperin, J L, Fuster, V. Mechanism of action and pharmacology of unfractionated heparin. Arteriosclerosis, Thrombosis, and Vascular Biology. 2001; 21:1094–6.CrossRefGoogle ScholarPubMed
Choay, J, Petitou, M, Lormeau, JC, et al. Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochemical and Biophysical Research Communications. 1983; 116:492–9.CrossRefGoogle ScholarPubMed
Crowther, M A, Warkentin, T E. Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: Focus on new anticoagulant agents. Blood. 2008; 111:4871–9.CrossRefGoogle ScholarPubMed
Watanabe, M, Siddiqui, F M, Qureshi, A I. Incidence and management of ischemic stroke and intracerebral hemorrhage in patients on dabigatran etexilate treatment. Neurocritical Care. 2012; 16:203–9.CrossRefGoogle ScholarPubMed
Baz, R, Mekhail, T. Disorders of platelet function and number. 2010.CrossRefGoogle Scholar
Konkle, B A. Acquired disorders of platelet function. ASH Education Program Book. 2011; 391–6.CrossRefGoogle Scholar
Kenney, B, Stack, G. Drug-induced thrombocytopenia. Archives of Pathology and Laboratory Medicine. 2009; 133:309–14.CrossRefGoogle ScholarPubMed
Steiner, T, Poli, S, Griebe, M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage (INCH): a randomized trial. Lancet. 2016; 15:566–73.Google Scholar
Pollack, C V, Reilly, P A, Eikelboom, J, et al. Idarucizamab for dibigatran reversal. New England Journal of Medicine. 2015; 373:511–20.CrossRefGoogle Scholar

Accessibility standard: Unknown

Why this information is here

This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.

Accessibility Information

Accessibility compliance for the PDF of this book is currently unknown and may be updated in the future.

Save book to Kindle

To save this book to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×